title: Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
abstract: To assess the efficacy and toxicity of HAA regimen (homoharritonine 4 mg/m2/day, days 1-3; cytarabine 150 mg/m2/day, days 1-7; aclarubicin 12 mg/m2/day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered into this clinical study. The median follow-up was 26 months. Eighty-three percent of patients achieved complete remission (CR), and the first single course of induction HAA regimen resulted in CR rate of 79%. The CR rate of 100, 82 and 33% were achieved in patients with favorable, intermediate and unfavorable cytogenetics, respectively. For all patients who achieved CR, the median time from the initiation of the induction therapy to the evaluation of the remission status was 32 days. For all patients, the estimated 3 years overall survival (OS) rate was 53%, whereas for patients with M5, the estimated OS rate at 3 years was 75%. The toxicities associated with HAA regimen were acceptable, and the most common toxicity was infection. This study suggested that HAA regimen might be a well-tolerable, effective induction regimen in young adult patients with AML.
authors.affiliation: Department of Hematology, the First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang, PR China. jiej@hzcnc.com
authors.forename: J
authors.initials: J
authors.lastname: Jin
authors.forename: D-Z
authors.initials: DZ
authors.lastname: Jiang
authors.forename: W-Y
authors.initials: WY
authors.lastname: Mai
authors.forename: H-T
authors.initials: HT
authors.lastname: Meng
authors.forename: W-B
authors.initials: WB
authors.lastname: Qian
authors.forename: H-Y
authors.initials: HY
authors.lastname: Tong
authors.forename: J
authors.initials: J
authors.lastname: Huang
authors.forename: L-P
authors.initials: LP
authors.lastname: Mao
authors.forename: Y
authors.initials: Y
authors.lastname: Tong
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: Z-M
authors.initials: ZM
authors.lastname: Chen
authors.forename: W-L
authors.initials: WL
authors.lastname: Xu
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage / Q000009:adverse effects; D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006248:Harringtonines / Q000008:administration & dosage / Q000009:adverse effects; D000077863:Homoharringtonine; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged
chemical_list: D006248:Harringtonines; D003561:Cytarabine; D000077863:Homoharringtonine; D015250:Aclarubicin